Sutro Biopharma (STRO) EV/EBITDA: History & Chart

Sutro Biopharma, Inc.(STRO)

Biotechnology · South San Francisco, CA

$14.45-0.68 (-4.49%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Sutro Biopharma, Inc.

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.

South San Francisco, CA

128 employees

www.sutrobio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jane Chung

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Sutro Biopharma, Inc. (STRO)	$139.84M	N/A	N/A	N/A	N/A
Alpha Cognition Inc (ACOG)vs ›	$139.47M	N/A	N/A	N/A	N/A
Immuneering Corporation (IMRX)vs ›	$139.04M	N/A	N/A	N/A	N/A
KORU Medical Systems, Inc. (KRMD)vs ›	$137.80M	N/A	693.21x	347.06x	258.50x
Atrium Therapeutics, Inc. (RNA)vs ›	$136.67M	N/A	N/A	N/A	N/A
Nyxoah S.A. (NYXH)vs ›	$143.10M	N/A	N/A	N/A	N/A
Organigram Global Inc. (OGI)vs ›	$136.57M	10.66x	444.93x	542.94x	476.27x
Protara Therapeutics, Inc. (TARA)vs ›	$143.60M	N/A	44.23x	44.23x	44.23x
NervGen Pharma Corp. Common stock (NGEN)vs ›	$143.84M	N/A	N/A	N/A	N/A
Freenome, Inc. (FRNM)vs ›	$133.45M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Sutro Biopharma, Inc. (STRO)

$139.84M

N/A

Alpha Cognition Inc (ACOG)vs ›

$139.47M

N/A

Immuneering Corporation (IMRX)vs ›

$139.04M